Because we are not bound to a specific technology or platform, we can consider a wide range of programs and products with a focus on generating value and improving outcomes for patients dealing with infectious diseases.
Appili Therapeutics Inc. was specifically founded to advance the global fight against infectious disease. Our team follows a rigorous process to identify and evaluate drug development opportunities, and to ensure that they align optimally with unmet patient and market needs.
Without being bound to an indication or platform technology, we have the flexibility to deploy our ‘balanced risk’ approach to building our pipeline: a deliberate mix of close-to-market/revenue assets that provide near-term value and cash flow, coupled with cutting-edge, transformational programs that could change how we treat infectious disease.
Seeking additional programs that align with our balance risk portfolio strategy:
Near to market/revenue
or commercial opportunities
Transformational programs to tackle the most serious threats
An important aspect of this approach to portfolio-building is discipline – Appili’s team has reviewed and passed on more than 150 drug development projects that did not meet our rigorous scientific, clinical, patient-care, and strategic corporate criteria. The inherent flexibility in our approach also allows us to pursue opportunities that provide access to non-dilutive funding from government incentive programs or industry partnerships.